Gaudium IVF & Women Health IPO will raise ₹165.00 crore through a book-built process. The IPO consists of 1,13,92,500 Fresh Equity Shares (₹90.00 crore) and 94,93,700 Equity Shares offer-for-sale (OFS) (₹75.00 crore), at face value ₹5/share.
Gaudium IVF & Women Health IPO will open its bidding window on 20 February 2026 and will close on 24 February 2026. Gaudium IVF & Women Health Limited expects to allot the IPO shares on 25 February 2026 and list on 27 February 2026 on BSE & NSE.
Gaudium IVF & Women Health IPO set its price range at ₹75/share – ₹79/share. One lot comprises 189 shares, and this makes the minimum investment required by retail participants ₹14,931 (based on the upper price band).
Gaudium IVF & Women Health IPO: Details
| IPO Open | 20 February 2026 |
| IPO Close | 24 February 2026 |
| Face value | ₹5/share |
| Price Band | ₹75/share–₹79/share |
| Issue price | – |
| IPO Lot Size | 189 shares |
| Offer for sale | 94,93,700 Equity Shares (₹75.00 crore) |
| Fresh issue | 1,13,92,500 Equity Shares (₹90.00 crore) |
| Issue Type | Book-built/Mainboard |
| Listing | BSE & NSE |
| Total Issue Size (₹ Crore) | ₹165.00 crore (2,08,86,200 Equity Shares) |
| Minimum Retail Investment | ₹14,931 |
Gaudium IVF & Women Health IPO Timeline
| Bid Opening Date | 20 February 2026 |
| Bid Closing Date | 24 February 2026 |
| Allotment | 25 February 2026 |
| Refunds Initiated | 25 February 2026 |
| Share Credit Date | 26 February 2026 |
| Listing Date | 27 February 2026 |
| UPI mandate Cut-off time | 24 February 2026 (5 PM) |
Gaudium IVF & Women Health Key Performance Indicators (KPIs)
| KPIs | 2025 | 2024 | 2023 |
| ROE (%) | 41.31 | 38.23 | 59.51 |
| ROCE (%) | 39.37 | 38.74 | 54.4 |
| Debt-Equity Ratio (in times) | 0.41 | 0.58 | 0.43 |
| RoNW (%) | 59.11 | 39.3 | 41.71 |
| PAT Margin (%) | 6.96 | 21.43 | 30.56 |
| EBITDA Margin (%) | 40.48 | 40.25 | 45.36 |
| Price-Book Value | – | – | – |
Gaudium IVF & Women Health Limited Financial Information
| 2025 (in ₹ lakh) | 2024 (in ₹ lakh) | 2023 (in ₹ lakh) | |
| Revenue | 7,072.40 | 4,789.01 | 4,423.69 |
| Assets | 8,851.27 | 5,100.67 | 3,662.70 |
| Profit After Tax | 1,912.74 | 1,031.69 | 1,352.54 |
Subscription Status: Gaudium IVF & Women Health IPO
Subscription updates for the Gaudium IVF & Women Health IPO will be disclosed following the commencement of the bidding process.
Applications may be submitted during market hours, 10:00 AM to 5:00 PM on each day of the subscription period.
Gaudium IVF & Women Health IPO GMP
The Gaudium IVF & Women Health IPO GMP on 18 February 2026 is ₹12. The listing price is estimated at around ₹91/share (upper price band + today’s GMP), which keeps the expected profit at 15.19%.
The GMP trend today has moved downward. However, a strong listing is expected. Get the latest GMP trend data of the Gaudium IVF & Women Health IPO here!
| Date | GMP (₹) | Estimated Listing Price | Estimated Listing Gain | Trend |
| 18 February 2026 | ₹12 | ₹91 | ₹2,268 (15.19%) | ⬇️Decreasing |
| 17 February 2026 | ₹15 | ₹94 | ₹2,835 (18.99%) | ⬆️Increasing |
| 16 February 2026 | ₹0 | ₹0 | ₹ (0.00%) | – |
| 15 February 2026 | ₹0 | ₹0 | ₹ (0.00%) | – |
Note: GMP data comes from informal sources and fluctuates based on investor sentiment, market participation levels, and overall subscription momentum.
Gaudium IVF & Women Health IPO Reservation
Gaudium IVF & Women Health IPO shares are reserved in the following way:
| Category | Shares offered |
| Anchor Investors | – |
| QIBs | Maximum 50% |
| Retail Investors | Minimum 35% |
| NII shares offered (HNI) | Minimum 15% |
| Total | 100% |
Lot Size for the Gaudium IVF & Women Health IPO
Applicants are required to submit bids for at least 189 equity shares, with any additional investment permitted only in multiples of this base lot size.
| Application | Lot Size | Shares | Amount(in ₹) |
| Retail Investors Minimum Application | 1 | 189 | ₹14,931 |
| Retail Investors Maximum Application | 13 | 2,457 | ₹1,94,103 |
| S-HNI Minimum Application | 14 | 2,646 | ₹2,09,034 |
| S-HNI Maximum Application | 66 | 12,474 | ₹9,85,446 |
| B-HNI Minimum Application | 67 | 12,663 | ₹10,00,377 |
Anchor Investors Details: Gaudium IVF & Women Health IPO
| Bidding Opens On | 18 February 2026 |
| Shares to be Offered | – |
| Issue Size | – |
| 30 days expiry date for lock-in (50% shares) | March 2026 |
| 90 days expiry date for lock-in (Remaining 50% shares) | May 2026 |
Gaudium IVF & Women Health IPO Prospectus
About Gaudium IVF & Women Health Limited
Incorporated on 24 March 2015, Gaudium IVF & Women Health Limited is an Indian reproductive healthcare provider focused on assisted fertility treatments, particularly in vitro fertilisation.
Dr Manika Khanna, an infertility specialist with advanced surgical training, founded and leads the organisation as Chairperson and Managing Director. The company has its network across India using a hub-and-spoke framework. In early 2026, this network comprises over 30 locations, including 7 principal hubs and 28 spokes, functioning to extend clinical reach and patient access.
Its clinical portfolio comprises reproduction techniques such as IVF, ICSI, IUI, and ovulation induction, aimed at addressing varied causes of infertility across genders. Additionally, the company also delivers specialised women’s health services, including treatment for PCOD or PCOS, endometriosis, and clinical supervision of high-risk pregnancies.
| Book Running Lead Managers (BRLM) | Sarthi Capital Advisors Pvt Ltd |
| IPO Registrar | Bigshare Services Pvt Ltd |
Objectives of Gaudium IVF & Women Health
| Particulars | Amount (in ₹ lakh) |
| Establishment of New IVF Centres | 5,000.00 |
| Repayment loans availed by the Company | 2,000.00 |
| Corporate requirements | – |
Strengths Of Gaudium IVF & Women Health
- Patient-centred care framework: The company adopts an individualised treatment approach supported by counselling, confidentiality, transparency, and continuous patient assistance.
- Experienced clinical leadership: The company was founded by its senior infertility specialist with over two decades of expertise, supported by qualified gynaecologists and embryologists.
- Adoption of advanced medical technology: The company’s utilisation of next-generation laboratory systems and modern diagnostic equipment enhances its procedural precision and clinical outcomes.
- Technical proficiency in ultrasound-guided services: The company is capable of managing complex reproductive cases through specialised imaging and minimally invasive diagnostic interventions.
Risks of Gaudium IVF & Women Health
- Contingent liability: The company’s outstanding contingent liabilities relative to net worth may materially affect its financial stability if crystallised.
- Healthcare operational and reputational risk: The company’s specialised nature of fertility treatments subjects the company to medical, legal, and reputational uncertainties.
- Dependence on medical professionals: The company’s high employee attrition and reliance on specialist doctors may affect its service continuity and cost structures.
- Related party transaction risk: The company’s ongoing related party dealings may create potential conflicts of interest and governance concerns.
Gaudium IVF & Women Health IPO Review
The Gaudiu, IVF & Women Health IPO represents a specialised reproductive healthcare provider demonstrating revenue growth and sustained profitability over recent years. The company’s return ratios are strong and supported by moderate leverage levels.
The issue comprises both fresh capital and an offer-for-sale, with proceeds partly allocated towards expansion and debt reduction. The investors should assess the valuation, margin sustainability, clinical dependence risk, and regulatory aspects before forming an investment conclusion.
Other Recent IPO List
Here’s a list of open or scheduled to open IPOs in India in 2026!
| PNGS Reva Diamond Jewellery IPO | Fractal Analytics IPO |
| Marushika Technologies IPO | Grover Jewells IPO |
| PAN HR Solutions IPO | CKK Retail Mart IPO |
| Aye Finance IPO | Biopol Chemicals IPO |
Gaudium IVF & Women Health IPO FAQs
The Gaudium IVF & Women Health IPO is a mainboard book-built public issue aggregating ₹165.00 crore through a fresh issue of equity shares and an offer-for-sale, proposed for listing on BSE and NSE.
Investors can apply for the Gaudium IVF & Women Health IPO through ASBA-enabled bank accounts or authorised brokerage platforms using UPI authentication during the subscription window, subject to prescribed lot size requirements.
Investment suitability for the Gaudium IVF & Women Health IPO depends on its pricing, consistency in the financial performance of the company, expansion strategy, healthcare sector risks, and individual portfolio objectives. Investors shall carefully evaluate these factors before making any investment decision.
Based on the recent GMP trends of the Gaudium IVF & Women Health IPO, a moderate level of listing gains is projected. However, actual returns will depend on subscription demand, pricing dynamics, and broader market conditions.
The Gaudium IVF & Women Health IPO is scheduled to open for subscription on 20 February 2026 and close on 24 February 2026.
The minimum application lot size for the Gaudium IVF & Women Health IPO is 189 shares, with bids required in multiples of this base quantity.
The Gaudium IVF & Women Health IPO is expected to be finalised on 25 February 2026, subject to regulatory and procedural completion.
The shares of Gaudium IVF & Women Health are proposed to be listed on 27 February 2026 on the BSE and NSE, following allotment and share credit.
